Sabra Health Care REIT (SBRA) stock slips in premarket after naming new chief investment officer
6 January 2026
1 min read

Sabra Health Care REIT (SBRA) stock slips in premarket after naming new chief investment officer

New York, Jan 6, 2026, 08:00 EST — Premarket

  • SBRA down 0.4% premarket after Sabra names Darrin Smith chief investment officer
  • Filing shows CFO Michael Costa adds treasurer role; Smith’s base salary set at $470,000
  • Focus shifts to next quarterly results for updates on deal flow, funding costs and outlook

Shares of Sabra Health Care REIT, Inc. fell 0.4% to $19.08 in premarket trading on Tuesday after the healthcare landlord disclosed a chief investment officer transition. A regulatory filing showed Darrin Smith will also serve as secretary and executive vice president, while Chief Financial Officer Michael Costa takes on the treasurer role, effective Jan. 1. The filing said Smith’s employment agreement sets an initial annual base salary of $470,000 and outlines severance terms. 1

The change matters because the CIO job typically shapes a REIT’s deal pipeline — what it buys, sells, and how it funds growth. For dividend-focused real estate investment trusts, capital allocation can have a direct impact on cash flow and debt costs, both of which investors track closely.

Sabra’s CEO Rick Matros said the company has “a healthy pipeline of investment opportunities,” as it hands the investment brief to a long-tenured executive. Sabra owns and invests in healthcare real estate, including senior housing and skilled nursing facilities, and said Talya Nevo-Hacohen is retiring after serving as CIO. 2

Smith, 56, had served as Sabra’s executive vice president of investments since 2020, according to the filing. He previously worked at HCP Inc — now Healthpeak Properties — and earlier held roles at GE Capital Real Estate and Ernst & Young.

Other U.S. healthcare REITs were mixed in premarket trading, with Welltower and Ventas down about 1.2% each, while Healthpeak rose about 1.2%, suggesting stock-specific factors were in focus alongside broader rate sensitivity.

SBRA is trading near the top of its recent range, with StockAnalysis.com showing a 52-week span of $15.60 to $19.97. That proximity can make the shares more reactive to incremental news — and to shifts in bond yields that often sway REIT valuations. 3

But the market’s read on the shuffle may hinge less on titles and more on execution: whether Sabra can keep underwriting discipline as funding costs move and operators’ rent coverage remains under scrutiny across healthcare real estate.

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
AEVA stock jumps 25% premarket after Nvidia DRIVE Hyperion win, Omni LiDAR launch at CES 2026
Previous Story

AEVA stock jumps 25% premarket after Nvidia DRIVE Hyperion win, Omni LiDAR launch at CES 2026

AbbVie stock flat premarket after Canada OKs Maviret for acute hepatitis C — what investors watch next
Next Story

AbbVie stock flat premarket after Canada OKs Maviret for acute hepatitis C — what investors watch next

Go toTop